Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Merck KGaA to Add Mobius® Single-Use Bioreactor to Wuxi Plant

publication date: Feb 26, 2018

Merck KGaA of Germany announced it would make an additional investment to speed up construction of its Wuxi biologic drug manufacturing plant, including a Mobius® single-use bioreactor. The company said the bioreactor would serve biosimilar development in China. It paired the facility in Wuxi with the recently completed Nantong Life Science Center, which makes high-purity inorganic salts, cell culture media products and ready-to-use media for drug discovery and production. More details....

Stock Symbol: (Xetra: MRK)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.